Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

Monday, June 2, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced positive preclinical data for its Lu177-B7H3-mAb, indicating promising results that could enhance targeted therapies. This development may pave the way for further clinical studies and potential advancements in cancer treatment. The company is actively pursuing its research and development goals in this area.
Price reaction · baseline $5.26 (2025-06-02T18:32:00.000Z) · hit during market hours · 2 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive preclinical data reported for Lu177-B7H3-mAb.
  • Potential for significant advancements in targeted therapy.
  • Encouraging results may lead to further clinical studies.

Full Press Release Details

• Announcements
• Price Sensitive
• June 2, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• February 6, 2024
• Announcements
• February 6, 2024
• Announcements
• February 14, 2024
• Announcements
• November 26, 2021

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is Lu177-B7H3-mAb?

Lu177-B7H3-mAb is a targeted therapy aimed at treating cancer.

What were the results of the preclinical study?

The preclinical study reported positive data, indicating promising outcomes.

What is the significance of this announcement?

This announcement suggests potential advancements in targeted cancer therapies.

Is there a plan for further clinical studies?

Yes, the positive results may lead to further clinical studies.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics preclinical data Lu177-B7H3-mAb targeted therapy cancer treatment
Last updated: Jun 2, 2025